Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model
- 1 August 2007
- journal article
- Published by Elsevier in Experimental Hematology
- Vol. 35 (8) , 1201-1208
- https://doi.org/10.1016/j.exphem.2007.05.007
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Antibody-mediated acquired pure red cell aplasia (PRCA) after treatment with darbepoetinNephrology Dialysis Transplantation, 2007
- Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemiaExperimental Hematology, 2006
- Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteersBlood, 2006
- Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risksNephrology Dialysis Transplantation, 2005
- Standard of Care for Cancer-Related Anemia: Improving Hemoglobin Levels and Quality of LifeOncology, 2005
- The detection of anti-erythropoietin antibodies in human serum and plasma: Part I. Validation of the protocol for a radioimmunoprecipitation assayJournal of Immunological Methods, 2003
- Lessons from Eprex for biogeneric firmsNature Biotechnology, 2003
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Small Peptides as Potent Mimetics of the Protein Hormone ErythropoietinScience, 1996
- Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietinThe Lancet, 1990